Highlights RenovoRx, Inc.

Equities

RNXT

US75989R1077

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.4 ^USD	+2.19%		-0.71%	-38.86%

Apr. 16	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	CI
Apr. 15	RenovoRx, Inc. announced that it has received $11.136652 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	Apr. 16	CI
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer	Dec. 21	CI
RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform	Dec. 13	CI
RenovoRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Renovorx and Imugene Announces Researchcollaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion Platform	23-07-20	CI
RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer	23-06-29	CI
Renovorx, Inc. Initiates Patient Enrollment At University of Texas Southwestern Medical Center for Pivotal Phase III Tiger-Pac Clinical Trial	23-06-01	CI
RenovoRx, Inc. Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer	23-05-25	CI
RenovoRx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
RENOVORX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-31	AQ
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-02	CI
Renovorx, Inc. Announces Initial Results from A Pharmacokinetic (PK) Substudy Within the Phase III Un-Blinded Randomized Control Tiger-Pac Clinical Trial	23-01-18	CI
RenovoRx Reports Third Quarter 2022 Financial Results	22-11-14	BU
RENOVORX, INC. : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-14	AQ
RenovoRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
RenovoRx : Reports Second Quarter 2022 Financial Results - Form 8-K	22-08-15	PU
RenovoRx Reports Second Quarter 2022 Financial Results	22-08-15	BU
RENOVORX, INC. : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights RenovoRx, Inc.

Equities

RNXT

US75989R1077

Highlights

Filters